中国临床药学杂志

参考文献

[1]MONTANI D,CHAUMAIS M C,SAVALE L,et al.Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension[J].Adv Ther,2009,26(9):813.

[2]WRIGHT P J.Comparison of phosphodiesterase type 5(PDE5)inhibitors[J].Int J Clin Pract,2006,60(8):967.

[3]RING B J, PATTERSON B E,MITCHELL M I,et al.Effect of tadalafil on cytochrome P450 3A4-mediated clearance:studies in vitro and in vivo[J].Clin Pharmacol Ther,2005,77(1):63.

[4]GHOFRANI H A,VOSWINCKEL R,REICHENBERGER F,et al.Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension:a randomized prospective study[J].J Am Coll Cardiol,2004,44(7):1488.

[5] AGGARWAL P,PATIAL R K,NEGI P C,et al.Oral tadalafil in pulmonary artery hypertension:a prospective study[J].Indian Heart J,2007,59(4):329.

[6]GALIE N, BRUNDAGE B H,GHOFRANI H A,et al.Tadalafil therapy for pulmonary arterial hypertension[J].Circulation,2009,119(22):2894.

[7]PEPKE-ZABA J, BEARDSWORTH A,CHAN M,et al.Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension[J].Curr Med Res Opin,2009,25(10):2479.

[8]OUDIZ R J, BRUNDAGE B H,GALIE N, et al.Tadalafil for the treatment of pulmonary arterial hypertension:a double-blind 52-week uncontrolled extension study[J].J Am Coll Cardiol,20 12,60(8):768.

[9]中华医学会心血管病学分会肺血管病学组,中华心血管病杂志编辑委员会.中国肺高血压诊断和治疗指南2018[J].中华心血管病杂志,2018,46(12):933.

[10]GALIE N, BARBERA J A,FROST A E,et al.Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension[J].N Engl J Med,2015,373(9):834.

[11] D'ALTO M,ROMEO E,ARGIENTO P,et al.Initial tadalafil and ambrisentan combination therapy in pulmonary arterial hypertension:cLinical and haemodYnamic long-term efficacy(ITALY study)[J].J Cardiovasc Med(Hagerstown),2018,19(1):12.

[12]ZHUANG Y G,JIANG B J,GAO H,et al.Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension[J].Hypertens Res,2014,37(6):507.

[13]郑俊敏,余雄杰,连姝文.安立生坦联合他达拉非治疗肺动脉高压的有效性和安全性研究[J].中国医药科学,2019,9(20):7.

[14]郭建洲,马琰琰,王志伟.他达拉非联合波生坦治疗先天性心脏病手术后肺动脉高压患者的临床效果及心功能变化[J].岭南心血管病杂志,2018,24(1):40.

[15]张德振,韦安猛.波生坦联合他达拉非对肺动脉高压患者活动耐力和心功能的影响[J].中国临床医生杂志,2020,48(5):566.

[16]张向荣.波生坦联合他达拉非治疗肺动脉高压的疗效观察[D].石河子:石河子大学,2018.

[17]SITBON O, COTTIN V, CANUET M, et al.Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension[J].Eur Respir J,2020,56(3):2000673.

[18]张曹进,黄奕高,黄涛,等.伊诺前列素联合小剂量他达那非治疗成人先天性心脏病并重度肺动脉高压的单中心、开放、对照研究[J].中华心血管病杂志,2014,42(6):474.

[19]D'ALTO M,BADAGLIACCA R,ARGIENTO P,et al.Risk reduction and right heart reverse remodeling by upfront triple combination therapy in pulmonary arterial hypertension[J].Chest,2020,157(2):376.

[20]SITBON O,SATTLER C,BERTOLETTI L,et al.Initial dual oral combination therapy in pulmonary arterial hypertension[J].Eur Respir J,2016,47(6):1727.

[21]FRANTZ R P,DURST L,BURGER C D,et al.Conversion from sildenafil to tadalafil:results from the sildenafil to tadalafil in pulmonary arterial hypertension(SITAR)study[J].J Cardiovasc Pharmacol Ther,2014,19(6):550.

[22]LICHTBLAU M,HARZHEIM D,EHLKEN N,et al.Safety and longterm efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension[J].Lung,2015,193(1):105.

[23]TAKATSUKI S,CALDERBANK M,IVY D D.Initial experience with tadalafil in pediatric pulmonary arterial hypertension[J].Pediatr Cardiol,2012,33(5):683.

[24]SABRI M R,BEHESHTIAN E.Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension[J].Pediatr Cardiol,2014,35(4):699.

[25]SHLOBIN O A,BROWN A W,WEIR N, et al.Transition of PH patients from sildenafil to tadalafil:feasibility and practical considerations[J].Lung,2012,190(5):573.

[26]SHAPIRO S,TRAIGER G,HILL W,et al.Safety,tolerability,and efficacy of overnight switching from sildenafil to tadalaafil in patients with pulmonary arterial hypertension[J].Cardiovasc Ther,2013,31(5):274.

[27]MUKHOPADHYAY S, SHARMA M,RAMAKRISHNAN S, et al.Phosphodiesterase-5 inhibitor in Eisenmenger syndrome:a preliminary observational study[J].Circulation,2006,114(17):1807.

[28]MUKHOPADHYAY S,NATHANI S,YUSUF J,et al.Clinical efficacy of phosphodiesterase-5 inhibitor tadalaafil in Eisenmenger syndrome:a randomized,placebo-controlled,double-blind crossover study[J].Congenit Heart Dis,2011,6(5):424.

[29]BHARANI A,PATEL A,SARAF J,et al.Efficacy and safety of PDE-5inhibitor tadalafil in pulmonary arterial hypertension[J].Indian Heart J,2007,59(4):323.

[30]赵颖,谷新顺,李薇薇,等.他达拉非对结缔组织病相关肺动脉高压临床疗效观察[J].心肺血管病杂志,2020,39(5):554.

[31]HASSOUN P M,ZAMANIAN R T,DAMICO R,et al.Ambrisentan and tadalafil up-front combination therapy in Scleroderma-associated pulmonary arterial hypertension[J].Am J Respir Crit Care Med,2015,192(9):1102.

[32]YAMASHITA Y,TSUJINO I,SATO T,et al.Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension[J].World J Hepatol,2014,6(11):825.

[33]SHIVA A,SHIRAN M,RAFATI M,et al.Oral tadalafil in children with pulmonary arterial hypertension[J].Drug Res(Stuttg),2016,66(1):7.

[34]SABRI M R,BIGDELIAN H,HOSSEINZADEH M,et al.Comparison of the therapeutic effects and side effects of tadalafil and sildenafil after surgery in young infants with pulmonary arterial hypertension due to systemic-to-pulmonary shunts[J].Cardiol Young,2017,27(9):1686.

[35]YAMAZAKI H,KOBAYASHI N,TAKETSUNA M,et al.Safety and effectiveness of tadalafil in patients with pulmonary arterial hypertension:Japanese post-marketing surveillance data[J].Curr Med Res Opin,2017,33(5):963.

[36]COGHLAN J G, GALIE N, BARBERA J A,et al.Initial combination therapy with ambrisentan and tadalafil in connective tissue diseaseassociated pulmonary arterial hypertension(CTD-PAH):subgroup analysis from the AMBITION trial[J].Ann Rheum Dis,2017,76(7):1219.

[37]KUWANA M,BLAIR C,TAKAHASHI T,et al.Initial combination therapy of ambrisentan and tadalafil in connective tissue diseaseassociated pulmonary arterial hypertension(CTD-PAH)in the modified intention-to-treat population of the AMBITION study:post hoc analysis[J].Ann Rheum Dis,2020,79(5):626.

[38]SATO T,AMBALE-VENKATESH B,LIMA J A C,et al.The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in Scleroderma associated pulmonary arterial hypertension patients:cardiac magnetic resonance feature tracking study[J].Pulm Circ, 2018,8(1):2045893217748307.

[39]MERCURIO V,MUKHERJEE M,TEDFORD R J,et al.Improvement in right ventricular strain with ambrisentan and tadalafil upfront therapy in Scleroderma-associated pulmonary arterial hypertension[J].Am J Respir Crit Care Med,2018,197(3):388.

[40]GALIE N,DENTON C P,DARDI F,et al.Tadalafil in idiopathic or heritable pulmonary arterial hypertension(PAH)compared to PAH associated with connective tissue disease[J].Int J Cardiol,2017,235:67.

[41]SMALL D,FERGUSON-SELLS L,DAHDAH N, et al.Pharmacokinetics and safety of tadalafil in a paediatric population with pulmonary arterial hypertension:a multiple ascending-dose study[J].Br J Clin Pharmacol,2019,85(10):2302.

[42]FDA.Adcirca(tadalafil)label [EB/OL].Silver Spring:FDA,2018.(2009-05-22)[2020-09-22].https://www.accessdata.fda.gov/drugsatfda docs/label/2009/0223321bl.pdf.

[43]BERMAN-ROSENZWEIG E,ARNESON C,KLINGER J R.Effects of dose and age on adverse events associated with tadalafil in the treatment of pulmonary arterial hypertension[J].Pulm Circ,2014,4(1):45.